CA-EV-CONNECT
With 5.7 million electric vehicles (EVs) anticipated to be used in fleet applications by 2025, EV Connect, a leading EV charging business platform, and bp pulse, a global leader in charging infrastructure for fleets and public charging, today announced a collaboration to bring key capabilities of Omega, bp pulse's EV charge management software, to the EV Connect platform. Tailored to the diverse charging requirements and duty cycles of EV fleets, Omega delivers a comprehensive managed charging solution that integrates state-of-the-art charging management technology from EV Connect and bp pulse into a new, comprehensive fleet offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521725993/en/
The collaboration gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization. (Graphic: Business Wire)
With bp pulse and EV Connect’s Omega integration, fleet operators can focus on their core business while Omega orchestrates charging schedules, prioritizes charging based on fleet needs, and enables real-time insights for informed decision-making, whether charging at depots, on the go, or at driver homes. The collaboration between bp pulse and EV Connect gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization.
"At bp pulse, we remain steadfast in our mission to simplify electrification for diverse fleets, and collaborating with EV Connect on this endeavor marks an exciting milestone, expanding our scope to deliver turnkey solutions for fleet operators industry-wide," said Sujay Sharma, CEO of bp pulse Americas. “Our shared goal is to provide fleet customers with a comprehensive solution that addresses all aspects of their charging needs—no matter the location. This collaboration allows us to combine our unique offerings into one cohesive platform."
Omega orchestrates EV charging to optimize cost-effective charging for fleets, while the EV Connect platform focuses on managing financial transactions, particularly in commercial fleet settings. This includes fleet operations in which drivers bring vehicles home, requiring private chargers with simple reimbursement options. By combining the capabilities of Omega and the EV Connect platform, fleet operators, including those in government, municipal, logistics, services, and sales sectors, can expect improved efficiency and optimization of their charging stations while empowering fleet managers with precise control over when and how their vehicles are charged, optimizing for factors like energy cost, power constraints, vehicle readiness, and operational efficiency.
"This collaboration between EV Connect and bp pulse brings unparalleled expertise in the electric vehicle charging industry, opening doors to elevate our fleet management capabilities and deliver cutting-edge solutions that set new standards for both of our customers," said Jon Leicester, Vice President and Head of Commercial at EV Connect. "By integrating our platforms, we can offer a comprehensive management solution that caters to fleet operators looking to optimize electric fleet efficiency like never before."
EV Connect is the conduit to accelerating EV charging business growth with technology and tools that drive innovation to fuel new business models in e-mobility. To learn more about how EV Connect is helping businesses of all sizes unlock the power of EV charging business models, please visit www.evconnect.com.
About EV Connect
EV Connect is the all-in-one EV charging platform that delivers the tools to build, run, and scale EV charging businesses successfully. The platform serves a broad set of use cases for customers, including Charge Point Operators (CPOs), charging network providers, Fortune 500 companies, charging business upstarts and trailblazers, fleet-scale transportation providers, and electric utilities.
EV Connect customers benefit from a combination of cutting-edge software features with premium service experiences, such as branded customer support, EV charging station procurement, deployment and installation support, and the latest driver app technology. Because technology, public policy, and technical standards constantly evolve and change, EV Connect has built its platform and tools to ensure that an investment in electric vehicle charging equipment delivers exceptionally reliable performance, confidence in station utilization and revenue management, and return on investment. Founded in 2010, EV Connect offers the tools and connections for EV charging businesses of any size, with the power of an open-platform approach and a trusted partner network.
For more information, please visit www.evconnect.com and follow us on X and LinkedIn.
About bp pulse
bp pulse is bp’s electric vehicle (EV) charging business, rolling out fast, reliable charge points to consumers and commercial fleets around the world. Globally, bp pulse is one of the UK’s leading rapid and ultra-fast public EV charging networks. It also operates the largest number of sites with ultra-fast charging in Germany, with a growing charging point footprint in China and the Netherlands. The company aims to increase its network of public EV charging points by 2030 to over 100,000 worldwide.
bp pulse is bp’s electric vehicle (EV) charging business. Focused on fast and reliable charging, bp pulse deploys charging points for EV drivers and commercial fleets on the go; at destination hubs, at the depot and bp retail sites. Around the world bp pulse is working with some of the world’s biggest businesses, while developing the Gigahub™ network, a series of large EV high-speed charging hubs in high-demand locations. Electric vehicle charging is one of five growth engines of bp’s transformation into an integrated energy company. The company has already installed more than 27,000 charge points and aims to expand its network of public EV charging stations to more than 100,000 worldwide by 2030. In the US, bp is planning to invest up to $1 billion in EV charging by 2030. For more information, visit bppulsefleet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521725993/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom